Abnormalities in micturition: Difference between revisions
Jump to navigation
Jump to search
Line 116: | Line 116: | ||
| style="background: #DCDCDC; text-align: center;" |[[Urethritis]] | | style="background: #DCDCDC; text-align: center;" |[[Urethritis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 135: | Line 135: | ||
| style="background: #DCDCDC; text-align: center;" |[[Pyelonephritis]] | | style="background: #DCDCDC; text-align: center;" |[[Pyelonephritis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 154: | Line 154: | ||
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginitis]] | | style="background: #DCDCDC; text-align: center;" |[[Vulvovaginitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 173: | Line 173: | ||
| style="background: #DCDCDC; text-align: center;" |[[Cervicitis]] | | style="background: #DCDCDC; text-align: center;" |[[Cervicitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 191: | Line 191: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Prostatitis]] | | style="background: #DCDCDC; text-align: center;" |[[Prostatitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
Line 210: | Line 210: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Epididymoorchitis]] | | style="background: #DCDCDC; text-align: center;" |[[Epididymoorchitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 231: | Line 231: | ||
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Anatomic]] | ! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Anatomic]] | ||
| style="background: #DCDCDC; text-align: center;" |[[Urethral stricture]] | | style="background: #DCDCDC; text-align: center;" |[[Urethral stricture]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 250: | Line 250: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Benign prostatic hyperplasia|Benign prostatic hyperplasia (BPH)]] | | style="background: #DCDCDC; text-align: center;" |[[Benign prostatic hyperplasia|Benign prostatic hyperplasia (BPH)]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 270: | Line 270: | ||
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Drug]] | ! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Drug]] | ||
| style="background: #DCDCDC; text-align: center;" |[[Spermicide|Spermicides]] | | style="background: #DCDCDC; text-align: center;" |[[Spermicide|Spermicides]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 289: | Line 289: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Cyclophosphamide]] | | style="background: #DCDCDC; text-align: center;" |[[Cyclophosphamide]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 309: | Line 309: | ||
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Endocrine disorders]] | ! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Endocrine disorders]] | ||
| style="background: #DCDCDC; text-align: center;" |[[Atrophic vaginitis]] | | style="background: #DCDCDC; text-align: center;" |[[Atrophic vaginitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 328: | Line 328: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Endometriosis]] | | style="background: #DCDCDC; text-align: center;" |[[Endometriosis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 345: | Line 345: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Dysmenorrhea]] | |||
* [[Dyspareunia]] | |||
* [[Dyschezia]] | |||
|- | |- | ||
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Malignancy]] | ! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Malignancy]] | ||
| style="background: #DCDCDC; text-align: center;" |[[Bladder cancer]] | | style="background: #DCDCDC; text-align: center;" |[[Bladder cancer]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 367: | Line 370: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginal disorders|Vulvovaginal cancer]] | | style="background: #DCDCDC; text-align: center;" |[[Vulvovaginal disorders|Vulvovaginal cancer]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 388: | Line 391: | ||
| style="background: #DCDCDC; text-align: center;" |[[Genitourinary system|Genitourinary instrumentation]] | | style="background: #DCDCDC; text-align: center;" |[[Genitourinary system|Genitourinary instrumentation]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 406: | Line 409: | ||
|- | |- | ||
| style="background: #DCDCDC; text-align: center;" |[[Pelvic]] [[irradiation]] | | style="background: #DCDCDC; text-align: center;" |[[Pelvic]] [[irradiation]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 426: | Line 429: | ||
| style="background: #DCDCDC; text-align: center;" |[[Trauma]] | | style="background: #DCDCDC; text-align: center;" |[[Trauma]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | |
Revision as of 20:53, 28 June 2018
Micturation Abnormalities Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Classification
Causes
Abnormalities of Micturition Differential Diagnosis
Differentiating the diseases that can cause abnormality in micturition:
Abbreviations: N= Normal, UTI= Urinary tract infection, CBC= Complete blood count, CT= Computed tomography, IBS= Irritable bowel syndrome, DRE= Digital rectal examination,
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||||||
Lab Findings | Imaging | ||||||||||||||||||
Fever | Urinary symptoms | Supra-pubic tenderness | Skin lesions | Other | CBC | Electrolytes | Urinalysis | Ultrasonography | CT scan | Other | |||||||||
Dysuria | Frequency | Dribbling | Hesitancy | Nocturia | |||||||||||||||
Inflammatory | Dermatological disorders | Lichen sclerosus[1] | – | + | – | – | + | – | – | Lichenified plaques | – | N | N | often shows UTI in women | N | N | N | Biopsy | |
Behcet's syndrome[2][3][4] | – | + | + | – | + | + | – | N | N | N | N | N | None |
| |||||
Infectious diseases | Cystitis | + | + | + | + | + | + | + | N | Leukopenia | N | ||||||||
Urethritis | + | + | + | – | + | – | + | – | |||||||||||
Pyelonephritis | + | + | + | – | – | – | ± | ||||||||||||
Vulvovaginitis | + | + | + | + | + | - | – | ||||||||||||
Cervicitis | + | ± | ± | - | - | + | |||||||||||||
Prostatitis | + | + | + | + | + | + | |||||||||||||
Epididymoorchitis | + | + | + | ||||||||||||||||
Non-inflammatory | Anatomic | Urethral stricture | – | ||||||||||||||||
Benign prostatic hyperplasia (BPH) | – | + | + | + | + | + | – | ||||||||||||
Drug | Spermicides | – | |||||||||||||||||
Cyclophosphamide | – | + | |||||||||||||||||
Endocrine disorders | Atrophic vaginitis | – | |||||||||||||||||
Endometriosis | – | + | |||||||||||||||||
Malignancy | Bladder cancer | – | – | ||||||||||||||||
Vulvovaginal cancer | ± | – | |||||||||||||||||
Iatrogenic | Genitourinary instrumentation | + | – | ||||||||||||||||
Pelvic irradiation | – | ||||||||||||||||||
Trauma | ± | ± |
References
- ↑ Ventolini G, Patel R, Vasquez R (2015). "Lichen sclerosus: a potpourri of misdiagnosed cases based on atypical clinical presentations". Int J Womens Health. 7: 511–5. doi:10.2147/IJWH.S82879. PMC 4431497. PMID 26056492.
- ↑ Theodorou C, Floratos D, Hatzinicolaou P, Vaiopoulos G (August 1999). "Neurogenic bladder dysfunction due to Behçet's disease". Int. J. Urol. 6 (8): 423–5. PMID 10466456.
- ↑ Porru D, Pau AC, Scarpa RM, Zanolla L, Cao A, Usai E (May 1996). "Behçet's disease and the neuropathic bladder: urodynamic features: case report and a literature review". Spinal Cord. 34 (5): 305–7. PMID 8963981.
- ↑ Cetinel B, Akpinar H, Tüfek I, Uygun N, Solok V, Yazici H (January 1999). "Bladder involvement in Behçet's syndrome". J. Urol. 161 (1): 52–6. PMID 10037367.